Autoantibodies and immune complexes to oxidation-specific epitopes and progression of aortic stenosis: Results from the ASTRONOMER trial.

[1]  S. Crooke,et al.  Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials , 2016, The Lancet.

[2]  L. Joosten,et al.  Oxidized Phospholipids on Lipoprotein(a) Elicit Arterial Wall Inflammation and an Inflammatory Monocyte Response in Humans , 2016, Circulation.

[3]  S. Tsimikas,et al.  Lipoprotein(a) and oxidized phospholipids in calcific aortic valve stenosis , 2016, Current opinion in cardiology.

[4]  J. Witztum,et al.  Innate sensing of oxidation-specific epitopes in health and disease , 2016, Nature Reviews Immunology.

[5]  Y. Bossé,et al.  Autotaxin interacts with lipoprotein(a) and oxidized phospholipids in predicting the risk of calcific aortic valve stenosis in patients with coronary artery disease , 2016, Journal of internal medicine.

[6]  J. Witztum,et al.  Antisense therapy targeting apolipoprotein(a): a randomised, double-blind, placebo-controlled phase 1 study , 2015, The Lancet.

[7]  Y. Bossé,et al.  Oxidized Phospholipids, Lipoprotein(a), and Progression of Calci fi c Aortic Valve Stenosis , 2017 .

[8]  Y. Bossé,et al.  Autotaxin Derived From Lipoprotein(a) and Valve Interstitial Cells Promotes Inflammation and Mineralization of the Aortic Valve , 2015, Circulation.

[9]  C. Nievergelt,et al.  Heritability of Biomarkers of Oxidized Lipoproteins: Twin Pair Study , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[10]  B. Nordestgaard,et al.  Elevated Lipoprotein(a) Does Not Cause Low-Grade Inflammation Despite Causal Association With Aortic Valve Stenosis and Myocardial Infarction: A Study of 100,578 Individuals from the General Population. , 2015, The Journal of clinical endocrinology and metabolism.

[11]  D. Tsiantoulas,et al.  Atheroprotective immunization with malondialdehyde-modified LDL is hapten specific and dependent on advanced MDA adducts: implications for development of an atheroprotective vaccine1[S] , 2014, Journal of Lipid Research.

[12]  J. Mckenney,et al.  Effect of alirocumab, a monoclonal proprotein convertase subtilisin/kexin 9 antibody, on lipoprotein(a) concentrations (a pooled analysis of 150 mg every two weeks dosing from phase 2 trials). , 2014, The American journal of cardiology.

[13]  Thoralf M Sundt,et al.  2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Journal of the American College of Cardiology.

[14]  Thoralf M Sundt,et al.  2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[15]  R. Giugliano,et al.  Reduction in lipoprotein(a) with PCSK9 monoclonal antibody evolocumab (AMG 145): a pooled analysis of more than 1,300 patients in 4 phase II trials. , 2014, Journal of the American College of Cardiology.

[16]  M. Boffa,et al.  Determinants of binding of oxidized phospholipids on apolipoprotein (a) and lipoprotein (a)1 , 2013, Journal of Lipid Research.

[17]  B. Nordestgaard,et al.  Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. , 2013, Journal of the American College of Cardiology.

[18]  M. Sandhu,et al.  Lipoprotein(a) levels, genotype and incident aortic stenosis: a prospective Mendelian randomization study and replication in a case-control cohort , 2013 .

[19]  S. Body,et al.  Calcific aortic valve disease: a consensus summary from the Alliance of Investigators on Calcific Aortic Valve Disease. , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[20]  J. Witztum,et al.  Oxidation-specific epitopes and immunological responses: Translational biotheranostic implications for atherosclerosis. , 2013, Current opinion in pharmacology.

[21]  Kathleen F. Kerr,et al.  Genetic associations with valvular calcification and aortic stenosis. , 2013, The New England journal of medicine.

[22]  Qingbo Xu,et al.  Oxidation-specific biomarkers, prospective 15-year cardiovascular and stroke outcomes, and net reclassification of cardiovascular events. , 2012, Journal of the American College of Cardiology.

[23]  O. Alfieri,et al.  Guidelines on the management of valvular heart disease. , 2007, European heart journal.

[24]  J. Després,et al.  Impact of metabolic syndrome on progression of aortic stenosis: influence of age and statin therapy. , 2012, Journal of the American College of Cardiology.

[25]  Andrew C. Li,et al.  Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression. , 2011, Journal of the American College of Cardiology.

[26]  P. Talmud,et al.  Relationship of IgG and IgM autoantibodies and immune complexes to oxidized LDL with markers of oxidation and inflammation and cardiovascular events: results from the EPIC-Norfolk Study , 2011, Journal of Lipid Research.

[27]  Soo-Ho Choi,et al.  Oxidation-Specific Epitopes Are Danger-Associated Molecular Patterns Recognized by Pattern Recognition Receptors of Innate Immunity , 2011, Circulation research.

[28]  K. Teo,et al.  Effect of Lipid Lowering With Rosuvastatin on Progression of Aortic Stenosis: Results of the Aortic Stenosis Progression Observation: Measuring Effects of Rosuvastatin (ASTRONOMER) Trial , 2010, Circulation.

[29]  F. Bäckhed,et al.  Oxidation-specific epitopes are dominant targets of innate natural antibodies in mice and humans. , 2009, The Journal of clinical investigation.

[30]  J. Chambers,et al.  Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. , 2008, The New England journal of medicine.

[31]  G. Feuchtner,et al.  Prognosis and risk factors in patients with asymptomatic aortic stenosis and their modulation by atorvastatin (20 mg). , 2008, The American journal of cardiology.

[32]  S. Tsimikas,et al.  Antibodies to oxidized low density lipoprotein: epidemiological studies and potential clinical applications in cardiovascular disease. , 2007, Minerva cardioangiologica.

[33]  R. Prescott,et al.  A randomized trial of intensive lipid-lowering therapy in calcific aortic stenosis. , 2005, The New England journal of medicine.

[34]  C. Otto,et al.  Apolipoproteins B, (a), and E accumulate in the morphologically early lesion of 'degenerative' valvular aortic stenosis. , 1996, Arteriosclerosis, thrombosis, and vascular biology.

[35]  T. Mitsuhashi,et al.  Correlation between lipoprotein(a) and aortic valve sclerosis assessed by echocardiography (the JMS Cardiac Echo and Cohort Study). , 1995, The American journal of cardiology.